GSK on Wednesday announced it is restructuring an existing collaboration agreement with German biotech CureVac, focusing on their investigational mRNA vaccines for influenza and COVID-19 while withdrawing from other infectious disease projects. Under the amended...
Overview This review article discusses the therapeutic potential of gene editing, focusing on mRNA-based delivery systems. It highlights the advancements in gene editing technologies like CRISPR-Cas systems and base editors, and examines their applications in treating...
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company known for its innovative mRNA cell therapies targeting autoimmune diseases, announced today a significant milestone in its financial journey. The company has entered into a securities...
U.S. health officials announced Tuesday that the federal government will pay Moderna $176 million to speed development of a pandemic flu vaccine based on mRNA technology. Such a vaccine could be used to treat bird flu in people, as concern grows about H5N1 cases...
Innovative model highlights potential platform to develop novel therapies Researchers at Children’s Hospital of Philadelphia (CHOP) and the University of Pennsylvania Perelman School of Medicine pioneered a new model that offers a potential platform for...